Rebamipide NEW

Manufacturer Provide Rebamipide Anti Ulcer Raw Powder Rebamipide CAS 90098-04-7

Introduction

Product Name: Rebamipide

Other Name :(+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoica

CAS NO: 90098-04-7

Purity: 99%min
Appearance:White Powder

Molecular formula: C19H15ClN2O4

Molecular weight :370.79

Melting Point :288-290°C dec.

Boiling Point :695.0±55.0 °C(Predicted)

Density :1.394±0.06 g/cm3(Predicted)

Storage:Sealed in dry,Room Temperature

Rebamipide, also known as rebapide, is a new type of anti-ulcer drug. In 1990, it was first marketed in Japan as a drug for gastric ulcer and acute and chronic gastritis. Rebamipide is a gastric mucosal protectant, which can increase the blood flow of gastric mucosa, the synthesis of prostagland E2 and gastric mucus secretion.
It can promote the expression of epidermal grow factor and its receptor Chemicalbook, prevent ulcer and promote ulcer healing.

Application 

(1) Prevention and treatment of gastric mucosal damage caused by NSAIDs Rebamipide has a significant reversal of the side effects such as decreased gastric mucosal prostaglandin production and increased mucosal permeability caused by NSAIDs.  Moreover, studies have found that patients taking NSAIDs have high expression of HIF-1 in the epithelial gastric mucosa, indicating that the gastric mucosa is in a hypoxic-ischemic state;  while patients taking rebamipide have significantly lower HIF-1, indicating that rebamipide is taking NSAIDs The gastric mucosa of the patient has a good protective effect.  From this point of view, rebamipide may have a preventive and therapeutic effect on gastric mucosal damage caused by NSAIDs (especially non-selective NSAIDs) drugs.
(2) HP-related gastritis treatment Haruma et al. reported that in the clinical observation of 86 HP-positive patients, 53 patients taking Rebamipide significantly reduced the infiltration of gastric antrum and gastric corpus monocytes and mesitocytes , Gastric inflammation was significantly reduced compared with those who did not take the medicine, indicating that it has a good quality effect on HP-related gastritis.
(3) Other studies have reported that the body temperature of gastric cancer patients who took rebamipide before surgery was significantly lower than that of the control group, and the serum IL-6 content was also significantly lower than that of the control group, indicating that rebamipide has an effect on gastric cancer.  Systemic inflammatory response syndrome after surgery has a certain improvement effect;  Rebamipide may become a new treatment for ulcerative colitis;  it may become a new and effective treatment for Meniere's disease.